NEWSVERUM / Global briefing

Puits et forage · Newsverum

21 stories

Follow global economy, business, finance, energy, climate and public affairs through original sources, sourced data and context.

Filter results

Health

Only stories with data

Clear filters
Health

Solomon Islands trains 42 Guadalcanal health workers for emergencies

A five day course focused on keeping clinics operating through floods, cyclones and landslides. Earlier releases reported training cohorts of 38 in Temotu and 36 in Makira.

WHO media release on Guadalcanal health emergency training5 min read Data included
Health

Bracco reports 6 million global doses of VUEWAY gadopiclenol MRI contrast injection

Diagnostic imaging company Bracco announced that more than 6 million intravenous doses of VUEWAY (gadopiclenol) have been administered worldwide since its initial 2022 approval, following 2026 EU and U.S. pediatric extensions to term neonates and infants. The release also highlights the Max 3 injector and AiMIFY software, without disclosing product sales revenue.

Bracco Diagnostics, Bracco Delivers 6 Million VUEWAY (gadopiclenol) Injection Doses Worldwide as Its MRI Portfolio Continues to Evolve4 min read Data included
Health

Johnson & Johnson reports Phase 4 STAR trial gains for TREMFYA in axial psoriatic arthritis

Johnson & Johnson announced on 20 November 2026 that TREMFYA met primary and major secondary endpoints at Week 24 in the 411-patient Phase 4 STAR study of axial psoriatic arthritis, reducing BASDAI scores and MRI-assessed sacroiliac inflammation versus placebo.

Johnson & Johnson, Phase 4 STAR Study Results for TREMFYA in Axial Psoriatic Arthritis5 min read Data included
Health

PAQ Therapeutics presents first Phase 1 clinical data for KRAS G12D degrader PT0253 at ENA 2026

PAQ Therapeutics reported on 20 November 2026 preliminary Phase 1 results for its selective KRAS G12D degrader PT0253 in advanced solid tumors, showing no dose-limiting toxicities across 10 to 750 mg and early responses in monotherapy and first-line pancreatic cancer.

PAQ Therapeutics, First Clinical Data for PT0253 KRAS G12D Degrader at ENA 20264 min read Data included